Clinuvel Pharmaceuticals
Update in progressCUV.AX (ASX)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Clinuvel Pharmaceuticals is an Australian biopharmaceutical company focused on developing and commercializing treatments for genetic, metabolic, systemic, and life-threatening disorders. Its lead drug, SCENESSE, protects adults with erythropoietic protoporphyria from phototoxicity. The pipeline includes CUV9900, PRÉNUMBRA, and NEURACTHEL, plus melanocortin technology and photocosmetic products. Founded in 1999, it is based in Melbourne.
Company score
- Sentiment
- 0.34
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- 0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketASX (ASX)
- LocationAustralia
- CEODr. Philippe Jacques Wolgen M.B.A., M.D.
- Founded1999
- Websitewww.clinuvel.com
Identifiers
- ISINAU000000CUV3